Merck calls ACIP’s pneumococcal recommendation a ‘missed opportunity,’ advocates for expanding age group

The CDC’s Advisory Committee on Immunization Practices (ACIP) has recommended Merck’s recently approved 21-valent pneumococcal vaccine Capvaxive for adults 65 years and older, and for certain younger adults who have risk conditions or have already started a vaccine series.

Merck called the decision a “missed opportunity,” as the committee decided against broadening the recommendation to adults over 50 years old, at least for now. While ACIP discussed lowering the age recommendation, some speakers expressed concerns about making an already complicated recommendation more confusing.

“I think it would be really problematic to have a recommendation down to age 50 for a PCV21 vaccine and not for other high-valency pneumococcal vaccines such as PCV20,” said voting member Matthew Daley, who is a senior investigator at Kaiser Permanente’s Institute for Health Research. PCV20 is also known as Pfizer’s rival vaccine Prevnar 20.

Daley asked ACIP to discuss bringing down…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks